ClinicalTrials.gg
RecruitingNCT07945327Updated Nov 18, 2026

"Three-Dimensional MRI Analysis of Paraspinal Muscle Volume Following Radiofrequency Neurotomy in Chronic Lumbar Facet Syndrome: The Modulating Role of Exercise"

An interventional study of Lumbar Medial Branch Radiofrequency Neurotomy in Chronic Lumbar Facet Syndrome, sponsored by Ankara City Hospital Bilkent. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Ankara City Hospital Bilkent · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled May 2026, registered Oct 2026).
  • Started May 2026; still recruiting 6 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Study summary

Chronic lumbar facet syndrome is an important cause of persistent low back pain and functional limitation. Lumbar medial branch radiofrequency neurotomy (RFN) is a minimally invasive treatment used in patients with facet-mediated pain confirmed by diagnostic medial branch blocks. However, because the medial branch nerves also provide motor innervation to the multifidus muscle, the potential long-term effects of RFN on paraspinal muscle volume remain uncertain.

This prospective, randomized controlled trial aims to investigate changes in multifidus and erector spinae muscle volume following conventional lumbar medial branch RFN and to evaluate whether a home-based core stabilization exercise program influences these changes.

A total of 26 patients with chronic lumbar facet syndrome will be enrolled following a positive response, defined as at least a 50% reduction in pain intensity, to fluoroscopy-guided diagnostic lumbar medial branch block. All participants will undergo conventional lumbar medial branch RFN under fluoroscopic guidance. Following RFN, participants will be randomly assigned in a 1:1 ratio to either an RFN plus exercise group or an RFN-only group. The exercise group will receive a six-week home-based core stabilization exercise program, with adherence monitored through weekly telephone calls.

Magnetic resonance imaging (MRI) will be used to assess multifidus and erector spinae muscle volumes before RFN and at 12 months after treatment. MRI images will be analyzed using deep learning-based automatic segmentation and computer-assisted three-dimensional volumetric analysis, with muscle volumes calculated using voxel-based methods.

Pain intensity, lumbar range of motion, functional disability, health-related quality of life, neurological examination findings, and analgesic use will be assessed at baseline and at 1, 3, 6, and 12 months after RFN. The study will evaluate changes in paraspinal muscle volume following RFN and the potential contribution of core stabilization exercises to muscle volume preservation and clinical outcomes.

Read the detailed description

Background and Study Objectives Chronic lumbar facet syndrome is an important cause of persistent axial low back pain and functional disability. Lumbar medial branch radiofrequency neurotomy (RFN) is a minimally invasive treatment option for patients with suspected facet-mediated pain who demonstrate a positive response to diagnostic medial branch blocks. However, because the lumbar medial branch nerves also provide motor innervation to the multifidus muscle, RFN may affect paraspinal muscle morphology and function. The long-term effects of RFN on multifidus and erector spinae muscle volume remain uncertain.

In this study, deep learning-based three-dimensional MRI volumetric analysis will be used to assess paraspinal muscle volume. This advanced approach enables more comprehensive volumetric assessment and may reduce measurement errors and observer-related variability compared with conventional methods.

The primary objective of this prospective, randomized controlled trial is to evaluate changes in multifidus and erector spinae muscle volume following conventional lumbar medial branch RFN using magnetic resonance imaging (MRI) and deep learning-based three-dimensional volumetric analysis. The study will also investigate whether a six-week home-based core stabilization exercise program influences paraspinal muscle volume changes and clinical outcomes after RFN.

Study Population and Diagnostic Medial Branch Block A total of 26 patients aged 50-70 years with chronic axial low back pain and suspected lumbar facet syndrome will be enrolled after demonstrating a positive response to a diagnostic lumbar medial branch block.

Diagnostic medial branch blocks will be performed under fluoroscopic guidance with patients in the prone position. Target levels will be selected according to physical examination findings, areas of tenderness, lumbar MRI findings, and the anatomical innervation of the suspected painful facet joints. Unilateral or bilateral procedures will be performed according to the distribution of symptoms.

Following sterile preparation, local skin anesthesia will be administered using 2 mL of 1% lidocaine before needle insertion.

Needle placement near the junction of the superior articular process and transverse process, or at the appropriate anatomical target for the L5 dorsal ramus, will be confirmed using oblique, anteroposterior, and lateral fluoroscopic views.

Before administration of the diagnostic local anesthetic, 0.5 mL of radiopaque contrast medium will be injected under real-time fluoroscopy to exclude vascular uptake. Subsequently, 0.5 mL of 2% lidocaine will be injected at each target level.

Pain intensity will be assessed using the Visual Analog Scale (VAS) before the block and at 0, 2, 4, 6, and 8 hours after the procedure. Patients demonstrating at least a 50% reduction in pain intensity following the diagnostic block will be considered eligible for RFN and study enrollment. The diagnostic block is used to support the selection of patients with suspected facet-mediated pain for RFN.

Radiofrequency Neurotomy Procedure All enrolled participants will undergo conventional lumbar medial branch RFN under fluoroscopic guidance using standardized procedural parameters.

Before the procedure, heart rate, blood pressure, and oxygen saturation will be monitored. RFN will be performed with the patient in the prone position under sterile conditions. Following sterile preparation, 2 mL of 1% lidocaine will be administered for local skin anesthesia before RF cannula insertion.

A 20-gauge radiofrequency cannula with a 10-mm active tip (Abbott Medical, USA) will be advanced under ipsilateral oblique C-arm fluoroscopic guidance, with the cannula oriented parallel to the course of the target medial branch nerve. The cannula will be positioned in contact with bone near the junction of the superior articular process and transverse process. For the L5 dorsal ramus, the cannula will be positioned in the groove between the sacral ala and the superior articular process of S1.

Before lesioning, sensory stimulation will be performed at 50 Hz, aiming to elicit a sensory response at 0.5 V or less. Motor stimulation will then be performed at 2 Hz to confirm multifidus muscle contraction without lower-extremity muscle contraction.

Using a conventional radiofrequency generator (NeuroTherm NT1100, Neurotherm Inc., USA), thermal lesions will be created at 70°C for 90 seconds at each target nerve.

At the end of the procedure, 1 mL of 2% lidocaine will be injected through each cannula.

Participants will be observed for 30 minutes after RFN to monitor for potential complications and will be discharged if clinically stable.

Randomization and Exercise Intervention Following RFN, participants will be randomly assigned in a 1:1 ratio using a computer-generated randomization schedule to one of two groups, with 13 participants planned for each group.

Group 1 - RFN Plus Exercise: Participants will receive a six-week home-based core stabilization exercise program in addition to RFN. Exercises will be taught by a physiotherapist and will focus on lumbar core stabilization, including activation and strengthening of the lumbar stabilizing musculature. Adherence to the home exercise program will be assessed and documented through weekly telephone calls. Core stabilization exercises have been investigated for their effects on pain-related outcomes and lumbar muscle characteristics in patients with low back pain.

Group 2 - RFN Alone: Participants will undergo conventional lumbar medial branch RFN without receiving a study-specific core stabilization exercise program.

The RFN procedure and its technical parameters will be the same in both groups. MRI Assessment and Deep Learning-Based Volumetric Analysis Multifidus and erector spinae muscle volumes will be evaluated using lumbar MRI performed before RFN and at the 12-month follow-up.

MRI datasets in Digital Imaging and Communications in Medicine (DICOM) format will be processed using deep learning-based automatic segmentation. The multifidus and erector spinae muscles will be identified and segmented to generate muscle masks for quantitative volumetric assessment.

Spatial metadata from the DICOM images, including pixel spacing, slice thickness, and image position, will be used for voxel-based volume calculations. Rather than relying solely on two-dimensional cross-sectional measurements, the segmented MRI datasets will be evaluated using computer-assisted three-dimensional volumetric analysis. Muscle volumes will be expressed in cubic millimeters (mm³).

Baseline and 12-month muscle volumes will be compared to assess longitudinal changes in the multifidus and erector spinae muscles. Previous MRI-based investigations of paraspinal muscle changes following RFN provide a rationale for quantitative muscle assessment.

The imaging analysis will be performed by an engineer experienced in medical image processing who will be unaware of the spinal segments treated with RFN, as specified in the study protocol.

Clinical Outcome Assessments and Follow-Up Clinical evaluations will be performed before RFN (baseline) and at 1, 3, 6, and 12 months after treatment.

Primary outcome measures will include:

  • Changes in multifidus and erector spinae muscle volume between baseline and 12 months, assessed using MRI and deep learning-based volumetric analysis.
  • Changes in pain intensity measured using the VAS at rest, during movement, and at night.

Secondary outcome measures will include:

  • Lumbar range of motion.
  • Functional disability assessed using the Oswestry Disability Index (ODI).
  • Health-related quality of life assessed using the Nottingham Health Profile (NHP).
  • Neurological examination findings, including sensory function, motor strength, and deep tendon reflexes.
  • Analgesic use during follow-up. Clinical outcome measures will be evaluated at baseline and at 1, 3, 6, and 12 months after RFN. MRI-based muscle volume measurements will be obtained at baseline and 12 months.

Study Significance This study will investigate longitudinal changes in multifidus and erector spinae muscle volume following conventional lumbar medial branch RFN using MRI and deep learning-based three-dimensional volumetric analysis.

Because all participants will receive RFN, the randomized comparison will specifically evaluate the additional effect of a six-week home-based core stabilization exercise program on muscle volume changes and clinical outcomes. The findings may help clarify the relationship between post-RFN paraspinal muscle changes, exercise rehabilitation, and patient-reported outcomes over a 12-month follow-up period.

02

Conditions studied

  • Chronic Lumbar Facet Syndrome

Keywords

  • Lumbar Medial Branch Radiofrequency Neurotomy
  • Core Stabilization Exercise
  • Chronic Lumbar Facet Syndrome
  • Three-Dimensional Paraspinal Muscle Volume
03

In context

Lead sponsor

Ankara City Hospital Bilkent is the lead sponsor of 450 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 50 to 70 years.
  • Mechanical low back pain lasting more than 3 months.
  • A Visual Analog Scale (VAS) score ≥5 at baseline.
  • At least a 50% reduction in the Visual Analog Scale (VAS) score following fluoroscopy-guided diagnostic lumbar medial branch block.
  • Ability and willingness to provide written and comply with the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy.
  • Presence of implanted electronic devices, including a neurostimulator or cardiac pacemaker.
  • Diagnosis of an inflammatory rheumatic disease.
  • Polyneuropathy that may interfere with treatment or outcome assessment.
  • Active , a history of malignancy within the previous year, or current chemotherapy and/or radiotherapy.
  • Severe psychiatric disorders.
  • Severe coagulation disorders.
  • Active infection.
  • Skin disease at the intervention site.
  • Lumbar injection and/or physical therapy for low back pain within the previous 3 months.
  • Uncontrolled or severe cardiovascular or metabolic disease.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Lumbar Medial Branch Radiofrequency Neurotomy + Home-Based Core Stabilization Exercise Program

    Patients with chronic lumbar facet syndrome receiving conventional lumbar medial branch radiofrequency neurotomy followed by a standardized six-week home-based core stabilization exercise program.

    Procedure: Lumbar Medial Branch Radiofrequency Neurotomy

  • Active comparator
    Lumbar Medial Branch Radiofrequency Neurotomy

    Patients with chronic lumbar facet syndrome receiving conventional lumbar medial branch radiofrequency neurotomy without an additional exercise program.

    Procedure: Lumbar Medial Branch Radiofrequency Neurotomy

Interventions

  • ProcedureLumbar Medial Branch Radiofrequency Neurotomy

    Conventional lumbar medial branch radiofrequency neurotomy will be performed under fluoroscopic guidance using standard clinical techniques for the treatment of chronic lumbar facet syndrome.

06

What researchers measure

Primary outcomes

  1. Paraspinal Muscle Volume

    Change in multifidus and erector spinae muscle volumes (mm³) from baseline to 12 months following radiofrequency neurotomy, assessed using MRI and deep learning-based automatic segmentation with computer-assisted three-dimensional volumetric analysis.

    Time frame: Baseline and 12 months

  2. Pain Intensity (Visual Analog Scale, VAS)

    Change in pain intensity assessed using the Visual Analog Scale (VAS; 0-10) for pain at rest, during movement, and at night. Change in pain intensity assessed using the Visual Analog Scale (VAS; 0-10) for pain at rest, during movement, and at night. A score of 0 indicates no pain, and a score of 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months

Secondary outcomes

  1. Change in Lumbar Range of Motion Measured Using a Goniometer (Degrees)

    Change in lumbar flexion, extension, and right and left lateral flexion range of motion, measured using a goniometer and expressed in degrees (°). Each movement will be assessed separately.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months

  2. Oswestry Disability Index (ODI)

    Change in disability assessed using the Oswestry Disability Index (ODI), Version 2.0. Scores are calculated as percentages ranging from 0% (no disability) to 100% (maximum disability). Higher scores indicate greater functional disability.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months

  3. Nottingham Health Profile (NHP)

    Change in health-related quality of life assessed using the Nottingham Health Profile (NHP), consisting of 38 yes/no items across six domains: energy, pain, emotional reactions, sleep, social isolation, and physical mobility. Each domain is scored separately using weighted scoring from 0 (no problems) to 100 (maximum problems). Higher scores indicate poorer health-related quality of life.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months

  4. Analgesic Consumption

    Change in the type and frequency of analgesic use, including nonsteroidal anti-inflammatory drugs (NSAIDs), paracetamol, and opioid analgesics.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months

  5. Change in Lower Extremity Sensory Examination Findings

    Change in lower extremity sensory function assessed by clinical sensory examination and classified into three categories: normal sensation, hypoesthesia (decreased sensation), and hyperesthesia (increased sensation). Sensory function will be evaluated on the treated side in patients undergoing unilateral radiofrequency neurotomy (RFN) and bilaterally in patients undergoing bilateral RFN.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months

  6. Change in Lower Extremity Muscle Strength (MRC Scale, 0-5)

    Change in lower extremity muscle strength assessed using manual muscle testing and graded according to the Medical Research Council (MRC) scale, ranging from 0 (no muscle contraction) to 5 (normal muscle strength). Muscle strength will be assessed on the treated side in patients undergoing unilateral RFN and bilaterally in patients undergoing bilateral RFN.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months

  7. Change in Lower Extremity Deep Tendon Reflex Classification

    Change in patellar and Achilles deep tendon reflex findings assessed using a reflex hammer and classified into three categories: hypoactive (decreased reflex response), normal, and hyperactive (increased reflex response). Reflexes will be assessed on the treated side in patients undergoing unilateral RFN and bilaterally in patients undergoing bilateral RFN.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hlaing SS, Puntumetakul R, Khine EE, Boucaut R. Effects of core stabilization exercise and strengthening exercise on proprioception, balance, muscle thickness and pain related outcomes in patients with subacute nonspecific low back pain: a randomized controlled trial. BMC Musculoskelet Disord. 2021 Nov 30;22(1):998. doi: 10.1186/s12891-021-04858-6. PubMed 34847915 ↗
  • Oswald KAC, Ekengele V, Hoppe S, Streitberger K, Harnik M, Albers CE. Radiofrequency Neurotomy Does Not Cause Fatty Degeneration of the Lumbar Paraspinal Musculature in Patients with Chronic Lumbar Pain-A Retrospective 3D-Computer-Assisted MRI Analysis Using iSix Software. Pain Med. 2023 Jan 4;24(1):25-31. doi: 10.1093/pm/pnac103. PubMed 35775938 ↗
  • Almalki FA, Cortes DH. Multifidus Denervation After Radiofrequency Ablation of the Medial Nerve Alters the Biomechanics of the Spine-A Computational Study. J Appl Biomech. 2023 Aug 29;39(6):414-420. doi: 10.1123/jab.2022-0258. Print 2023 Dec 1. PubMed 37643753 ↗
  • Cohen SP, Raja SN. Pathogenesis, diagnosis, and treatment of lumbar zygapophysial (facet) joint pain. Anesthesiology. 2007 Mar;106(3):591-614. doi: 10.1097/00000542-200703000-00024. PubMed 17325518 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Oct 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2026
First posted
Nov 18, 2026
StartActual
May 14, 2026
Primary completionEst.
Oct 30, 2027
CompletionEst.
Oct 30, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945327
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
May 14, 2026
Primary completion
Oct 30, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

MUHAMMED FURKAN DAĞ
Contact
furkanduzce.38@gmail.com
+90 507 415 76 97
Bilge ÖZLEMİŞ, Prof. Dr.
Contact

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion